Skip to main content
TRILinactive

Trillium Therapeutics Inc.

Biopharma developer (SEC filing verified)

TRIL evidence brief

What we can confirm

BioSniper Score:
4.3 / 10
Lead Asset:
tti-621 (Phase 1)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 4.3 / 10 · Lead Asset: tti-621 (Phase 1)
BioSniper AIPage context preserved

Prepared research question

What matters most for TRIL—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

4.3/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

tti-621 (Phase 1)

Next Catalyst

—

Tracking 2 pipeline candidates for Trillium Therapeutics Inc..

Run Trillium Therapeutics Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Trillium Therapeutics Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity4.0

Lead: Phase 1

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company
923 active companies304,861 SEC filings22,725 clinical trials
Citation log window (7 days): 13,363 recorded LLM calls; 0 block events, 0 warning events. These counts do not measure factual accuracy or research quality.Computed at
How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.